By proceeding, you agree to our Terms of Use and Privacy Policy.
Robert joined MiNA as founding Chief Executive Officer in 2013. Robert has overseen MiNA’s growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners.
Talks About #Biotechnology
Preferred Locations #Europe
OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process.